title: [Intralesional pingyangmycin injection in the management of macrocystic lymphatic malformations in cervical region].
abstract: OBJECTIVE
  To investigate the therapeutic effects of pingyangmycin injection as a primary therapy of macrocystic lymphatic malformations in cervical region.
  
  
  METHODS
  Thirty-six patients with macrocystic lymphatic malformations in cervical region underwent the therapy of pingyangmycin injection between 2009 and 2012 at School of Stomatology, China Medical University. Among them, 16 patients had unilateral submandibular lesions, 20 patients had lesions in anterior cervical regions. The age of patients was from 6 months to 25 years old. The concentration of the drug was 1.6 mg /mL with an addition of lidocaine. The dose and cycle of treatment were dependent on the lesions' size and patients' age. The follow-up period was 12 months to 2 years after the last treatment.
  
  
  RESULTS
  The total effective rate was 100%, and the curative rate was 94.4%. No serious complications were encountered.
  
  
  CONCLUSIONS
  Intralesional Injection of pingyangmycin provides a safe and effective treatment for macrocystic lymphatic malformations in cervical region as a primary treatment.
authors.affiliation: Department of Oral and Maxillofacial Surgery, China Medical University, Shenyang, China. leierbao@sina.com
authors.forename: Bo-cheng
authors.initials: BC
authors.lastname: Lei
authors.forename: Xiao-bo
authors.initials: XB
authors.lastname: Gao
authors.forename: Zheng-yu
authors.initials: ZY
authors.lastname: Liu
authors.forename: Jing-jian
authors.initials: JJ
authors.lastname: Wei
authors.forename: Lei
authors.initials: L
authors.lastname: Xue
authors.forename: Xu-kai
authors.initials: XK
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D001761:Bleomycin / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D044148:Lymphatic Abnormalities; D009333:Neck; D019242:Oral Medicine; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001761:Bleomycin; C025703:bleomycetin